Tag: Biotechnology Industry

  • National Startup Day Shines a Light on Industries: Exploring India’s Progress, Government’s Role, and Future Visions in Growth

    As the sun rises on January 16, the nation proudly observes National Startup Day, a testament to India’s commitment to encouraging innovation and entrepreneurship. In 2022, Prime Minister Narendra Modi declared this day to celebrate the vibrant spirit of startups, acknowledging them as the backbone of a ‘New India.’ Since then, the startup landscape in the country has witnessed significant growth, with businesses sprouting across the nation.

    In 2016, the Indian government laid the foundation for this growth with the inception of the Startup India initiative. Today, India stands as the third-largest startup ecosystem globally, with over 1,12,718 DPIIT-recognized startups spread across 763 districts as of October 3, 2023. The nation not only ranks second in innovation quality but also excels in scientific publications and the quality of its universities among middle-income economies.

    In this context, StartupTalky connected with experienced individuals who have navigated the changing landscape of India’s startup ecosystem. In straightforward discussions, we explored their perspectives on India’s progress, the significant role played by the Government of India in driving growth, and their forward-looking views on the future of their respective industries. Their words reflect the pulse of a dynamic and ever-evolving entrepreneurial India.

    Fintech’s Evolution
    InsurTech’s Transformative Journey
    HR Industry’s Evolution
    Biotechnology’s Growth
    Tech and Electronics in India’s Startup Landscape
    Personal Care’s Sustainable Growth
    Fashioning Entrepreneurship in India

    Fintech’s Evolution

    Mr. Tarun Nazare, Co-Founder & CEO of Neokred Technologies, sharing fintech sector insights said, “Since 2016, we have witnessed the ecosystem go from boom to bust and bounce back. India’s startup landscape saw unicorns thrive, funding dip, and rebound. Now, the emphasis is on profitability with emerging sectors, promising resilient, innovative futures. Its advantages are that the Government is capitalistic, and focuses on the growth of all the sectors. Witnessed very active participation from RBI, regulator of Fintech. Expect mature decisions and good governance for yet-to-be-regulated sectors in the near future. We see promising activities from all the participants in all industries to make sure India’s GDP crosses more than $7 trillion by 2030.”


    Government Policies Lead Indian Startups to Thrive
    The government of India’s various initiatives and policies facilitate the growth of startups in India. Experts believe that government policies have made accessing capital easier.


    InsurTech’s Transformative Journey

    Kulin Shah, Co-founder and COO of Onsurity said, “Embarking on my entrepreneurship journey, witnessing the addition of over 68,000 startups, the space has undergone a transformative shift and evolved into leaders of product innovation. As the co-founder of an Insurtech, I’ve keenly observed the strategic initiatives that have propelled the rise of InsurTechs such as the regulatory framework, progressive policies, and initiatives. For example, with the introduction of the use and file process, insurers can introduce products to the market on filing with the regulator, thus avoiding a long waiting duration to get approvals. The introduction of regulatory sandboxes and streamlined licensing processes has further paved the way for growth.

    Our industry has transcended from a selling approach to a seamless, digital realm, where transactions unfold effortlessly at the click of a button. Insurtech platforms are no longer just facilitators of claims but are comprehensive service providers, offering a diverse array of insurance options with a strong emphasis on convenience and paperless processes.

    HR Industry’s Evolution

    Manish Panwar, Business Head, Vega HR, said, “India’s startup ecosystem has surged, driven by a young, dynamic, and talented workforce as well as increased funding, and government initiatives like Startup India. These measures include simplified regulations, tax benefits, and financial support, creating a conducive environment for innovation and entrepreneurship. The aim is to foster economic growth, and job creation, and position India as a global startup hub.

    “Cities like Bangalore, Delhi-NCR, Hyderabad, etc. are tech hubs, hosting diverse startups from fintech to ed-tech. Global attention and investment highlight India’s growing role in the global startup landscape.

    Panwar further added, “The future for the HR industry looks promising driven by a combination of government support, the startup boom, and the need for innovative talent management strategies. At Vega HR, we are passionate about creating solutions for employee rewards & recognition as well as enabling digital equity and streamline the process of ESOP management effortlessly. As companies recognize the importance of aligning employee interests with organizational success, total rewards (short-term & long-term) are expected to play a pivotal role in shaping the future of India’s corporate landscape, and we want to be at the forefront of steering this movement.

    Biotechnology’s Growth

    Mr. Najeeb Bin Haneef, Founder and CEO of Zaara Biotech, shares his perspective on the success of his startup and the broader landscape of the biotechnology industry. Reflecting on the system around him, Mr. Haneef states, “The success of my startup does not depend on my knowledge or luck; it is solely because of the system around me that supports my dream.

    He emphasizes the role of various support initiatives, events, and schemes introduced by the government that have been instrumental in the growth of Zaara Biotech. “The various schemes of the state and central government help us reach our products and services in domestic and international markets as easily as a student startup. From our inception, we have explored all privileges available to a student startup, allowing us to pitch and exhibit at various national and international events, with significant support from the state legacy, Kerala Startup Mission. 

    We presented our first product at GITEX Global in the Dubai World Trade Center under the Startup Mission scheme. There is always a boom in the startup ecosystem, and the government plays a vital role in creating synergies with international trade and exports. Research stations such as ICAR-CIFT Cochin also enable support for startups like us to reach a broader audience by placing products in various central government sectors. They also recommend participation in various training sessions funded by ICAR,of said Haneef.


    List Of Government Schemes for Startups in India
    Looking for financial assistance and resources for your startup? Check out our comprehensive list of government schemes for startups in India.


    EdTech’s Evolution

    Mr. Sumanth Prabhu, Co-founder & CEO of Ulipsu, shed light on the evolution of the EdTech industry in India. He said, “In 2014, the startup ecosystem was not this mature. There wasn’t much awareness about startups, funding, financial models, sales and marketing education, etc. Initially, it was a dream that merely existed but eventually, the startup ecosystem evolved. The startup knowledge, its concepts, the training and mentoring required can be found everywhere. The investing community has increased interest in startups today comparatively. Over the last decade, the government has made efforts to ensure that the startup ecosystem in India is thriving, and rightfully, it has matured today. With programs like the ‘Startup India Program’, different schemes have been available in different states all over India to foster the development of budding startups.

    “Existing startup policies and schemes that were available for companies irrespective of the EdTech industry, has helped us a lot. The Karnataka Government conducts an annual competition where deserving startups are given recognition along with financial grants as high as 50 lakh rupees. Ulipsu was also one of the participating companies in 2018 that was granted 20 lakh rupees. Likewise, a lot of such support initiatives and events were introduced by the government to expand growth,the said Prabhu.

    Highlighting the growth prospects of the ed-tech industry, Prabhu said, “Working in the ed-tech sector, the opportunities have increased drastically because of NEP implementation. We are aware about the future of education. Through NEP, there have been collaborations between the industry and academics. Much more awareness & preference is being given to skilling rather than rote learning. Multiple credit-based and entry-exit systems are helping children explore what they want to pursue. Learning outcomes are being influenced and catalyzed by AI. India, having the largest youth population in the world, is where education will show growth more rapidly than ever.

    Tech and Electronics in India’s Startup Landscape

    Sandeep Kumar, Founder and CEO, Baatu Tech, highlighting his startup journey said, “In my journey through India’s dynamic startup ecosystem, I’ve witnessed remarkable growth backed by substantial government support. India, now the world’s third-largest startup hub, has seen a surge in total funding from 2015-2022, with 108 Unicorns valued at multiple billions as of March 2023.

    “The government’s initiatives, such as startup challenges, National Startup Awards, Incubators and Accelerators, Networking opportunities, and state rankings, contribute significantly to this success. Startups with sustainable business models and those innovating around artificial intelligence, Software-as-a-Service (SaaS), and deep tech are anticipated to progress well. However, some challenges persist, particularly in funding, revenue generation, and supportive infrastructure,said Kumar.

    While discussing the way forward, Kumar emphasized, “The way forward necessitates pivotal roles for venture capitalists, angel investors, and the corporate sector. Policy measures, in alignment with the Digital India Initiative, are crucial. Bengaluru is a powerhouse in India’s startup ecosystem, hosting a remarkable 1,783 women-led startups, outpacing Mumbai (1,480) and Delhi (1,195), as reported by the startup data platform Tracxn. As India aims to become a global tech player, decisive policy measures and sustained support are vital for continued success, significantly beyond traditional sectors.


    Shaping Indian Finance: APIs, Government Strategies, and Industry Trends
    Explore the transformative impact of tailored APIs, government strategies, and industry trends on the financial services landscape in India.


    Personal Care’s Sustainable Growth

    Mr. Sanjeev Ingti, Director & Co-Founder of Eliea Wellness, sharing insights from the personal care industry, remarked, “During my journey, I’ve observed India’s remarkable strides in ecosystem studies. The nation has fostered a robust scientific community, embracing interdisciplinary research to understand and preserve its diverse ecosystems. Collaborations, technological advancements, and environmental policies showcase India’s commitment to sustainable development and biodiversity conservation. 

    The Indian government has actively propelled the medicinal personal care industry’s growth through policy initiatives, regulatory support, and incentives. Encouraging research and development, streamlining approvals, and fostering innovation have created a conducive environment for accelerated expansion, promoting health-centric products and contributing to the sector’s positive development.

    The future of India’s personal care industry promises innovation driven by technology, sustainability, and wellness trends. With a surge in demand for clean and natural products, the industry is poised for eco-friendly advancements. E-commerce and personalized solutions will further redefine consumer experiences, shaping a dynamic and health-conscious landscape.”

    Similarly, Mr. Lasakan Cholayil, Co-Founder of Sadhev, reflecting on the landscape of beauty and personal care startups, stated, “In my journey with Sadhev, I’ve seen firsthand the dynamic shift in India’s startup landscape. There’s a palpable energy, especially in our niche of organic beauty. It’s not just about business growth; it’s about a cultural shift towards sustainable living. We’re riding this wave, innovating and connecting with a community that values what we value.

    The Government of India has been a catalyst for us. Initiatives like ‘Make in India’ haven’t just been slogans; they’ve opened doors. We’ve seen tangible support in promoting indigenous products, which has been a game-changer for brands like ours. It’s about preserving our heritage while scaling up.

    Looking ahead, I see a horizon filled with opportunities. The trend is clear – there’s a growing demand for authentic, natural products. We’re not just selling products; we’re part of a larger movement towards sustainability. The market is ripe for innovation, and for startups like Sadhev, it’s a chance to lead this change, both in India and globally.

    Fashioning Entrepreneurship in India

    Dhruv Toshniwala, Founder of The Pant Project, discussing India’s startup ecosystem, said, “At The Pant Project, we’ve had the privilege of witnessing India’s remarkable strides in the startup ecosystem throughout our journey. Over the years, we’ve observed a significant surge in entrepreneurial spirit, fostering a vibrant and dynamic landscape. The government’s proactive measures, such as ‘Startup India’ and various policy reforms, have created a conducive environment for startups. These initiatives aim to simplify regulations, reduce bureaucratic hurdles, and provide financial incentives, fostering a more supportive ecosystem. Many startups in India are not only focused on profitability but also on creating positive social impact. This dual approach has led to the emergence of socially conscious businesses that strive to make a meaningful difference in society.

    Highlighting the Government’s role in accelerating growth in the fashion industry, Toshniwala said, “The Government’s emphasis on skill development and education has contributed to a skilled workforce. This, in turn, has enhanced productivity and efficiency within the industry, aligning with the nation’s broader economic goals. Investments in infrastructure, including logistics and transportation, have streamlined our supply chain operations. Government initiatives to promote international trade have opened up new avenues for our industry. Bilateral and multilateral trade agreements have facilitated smoother exports and imports, contributing to the overall growth of the sector. 

    “The digital landscape is transforming the way consumers shop. E-commerce, social media, and technology-driven experiences are shaping consumer behaviour. The Pant Project is strategically investing in digital platforms to enhance our online presence and provide a seamless shopping experience. The fashion industry in India is evolving towards greater inclusivity and diversity,added Toshniwala.

    In India’s startup journey, different businesses are growing with new ideas. From finance to fashion, they show how innovation and help from the government make a strong future. This is the story of a changing and hopeful world of startups in India.


    National Startup Day Spotlight: HealthTech & MedTech Evolution in India
    Explore the landscape of India’s healthcare industry on National Startup Day. Gain insights, understand govt support, and envision the future with industry experts


  • Biosplice Therapeutics: Developing First-in-Class, Small-Molecule Therapeutics

    Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Biosplice Therapeutics.

    Biotechnology has a wide array of applications impacting our daily lives. It contributes significantly to developing food products, medications, agricultural products, and more, using genetically modified organisms and clinical trials. The biotechnology industry is revolutionizing and growing, with numerous startups making big impacts in different fields, especially biopharmaceutical.

    One such globally recognized startup is Biosplice Therapeutics. It has transformed into the world’s most valuable US-based startup by researching and developing medicinal drugs for osteoarthritis, oncology, neurology, and other degenerative conditions.

    Let’s dig in to uncover more about Biosplice Therapeutics.

    Biosplice Therapeutics – Company Highlights

    Company Name Biosplice Therapeutics
    Headquarters San Diego, California, United States
    Sector Biotechnology
    Founders Osman Kibar
    Founded 2008
    Valuation $12 billion (2018)
    Website Biosplice.com

    About Biosplice Therapeutics
    Biosplice Therapeutics – Industry
    Biosplice Therapeutics – Founders and Team
    Biosplice Therapeutics – Startup Story
    Biosplice Therapeutics – Mission and Vision
    Biosplice Therapeutics – Business Model
    Biosplice Therapeutics – Revenue Model
    Biosplice Therapeutics – Products and Services
    Biosplice Therapeutics – Challenges Faced
    Biosplice Therapeutics – Funding and Investors
    Biosplice Therapeutics – Growth
    Biosplice Therapeutics – Partners
    Biosplice Therapeutics – Competitors

    About Biosplice Therapeutics

    Biosplice Therapeutics is a clinical-stage biotechnology company that develops first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing for major diseases.

    The California-based company is focused on osteoarthritis and oncology, along with early-stage programs in neurology and other areas of significant unmet medical need. It discovers new targets and biological processes in the Wnt pathway to develop small-molecule drugs that potentially address multiple degenerative conditions.

    Biosplice Therapeutics – Industry

    Biosplice Therapeutics operates in the Biotechnology industry, the global market size of which was approximately $1.22 trillion in 2022 and is projected to reach $3.21 trillion by 2030, with a remarkable CAGR of 12.8% during the forecasted period. With the rise of the biotechnology sector in developing countries like India, China, and Japan, the market is growing rapidly due to favorable government initiatives.

    Biotechnology Global Market Size, 2021 to 2030
    Biotechnology Global Market Size, 2021 to 2030

    Additionally, during the Covid-19 pandemic, the need for discovering novel solutions to develop vaccines and diagnostic tools to combat the disease increased. Some prominent companies capturing a significant share of the biotechnology industry are AstraZeneca, Gilead Sciences, Inc., Bristol-Myers Squibb, Sanofi, and Biogen.

    Biosplice Therapeutics – Founders and Team

    Osman Kibar is the founder of Biosplice Therapeutics.

    Osman Kibar

    Osman Kibar - Founder and Executive Chairman, Biosplice Therapeutics
    Osman Kibar – Founder and Executive Chairman, Biosplice Therapeutics

    Osman Kibar is the founder and Executive Chairman of Biosplice Therapeutics. He earned his B.S. in Electrical Engineering from Caltech and a B.A. in Mathematics and Economics from Pomona College. Moreover, he completed his M.S. and Ph.D. in Biophotonics and Optoelectronics from U.C. San Diego. Osman is an entrepreneur and inventor who founded multiple successful companies, including Genoptix, Dynamic Connections, and E-Tenna.

    Cevdet Samikoglu

    Cevdet Samikoglu - CEO, Biosplice Therapeutics
    Cevdet Samikoglu – CEO, Biosplice Therapeutics

    Cevdet Samikoglu is the CEO of Biosplice Therapeutics. He earned a B.A. in Economics from Hamilton College and completed MBD from Harvard Business School. Cevdet is the ex-Director of Research at Goldman Sachs and ex-Co-founder and Co-Portfolio Manager at Greywolf Capital Management. Before appointing Biosplice Therapeutics’ CEO, he worked as CFO and President at the company.

    Biosplice Therapeutics Team

    • Cevdet Samikoglu – Chief Executive Officer
    • Yusuf Yazici – Chief Medical Officer
    • Erich Horsley – Chief Financial Officer
    • Scott W. Bulcao – Chief Legal Officer

    Biosplice Therapeutics is a team of 120+ employees.

    Biosplice Therapeutics – Startup Story

    Biosplice Therapeutics was founded by Osman Kibar in 2008. Osman moved to San Diego in 2008 and incorporated the biotechnology company named Wintherix. He later rebranded the company as Samumed.

    The company made quite the entrance in 2016 with a $220 million war fund, a pipeline of anti-aging pharmaceuticals, and a whopping valuation of nearly $12 billion in 2018. Furthermore, it quietly changed its name to Biosplice Therapeutics in 2021 after adding another $120 million to its coffers.

    Biosplice Therapeutics enrolled for a Phase II clinical trial for Osteoarthritis treatment of the Knee in 2015 and successfully completed it in 2017. Moreover, the company completed a Phase I Study for Potential Idiopathic Pulmonary Fibrosis Treatment in 2017. It was in 2020 that Biosplice Therapeutics announced the publication of Phase 2 data on Lorecivivint. It initiated the New Phase 3 Trial for Knee Osteoarthritis in 2022. Additionally, the firm announced new clinical data for Cirtuvivint at the European Society for Medical Oncology Meeting in September 2022.

    Biosplice Therapeutics – Mission and Vision

    Biosplice Therapeutics aims to restore healthy by delivering first-in-class therapies harnessing alternative splicing.

    Biosplice Therapeutics – Business Model

    Biosplice Therapeutics’ scientific platform is based on biological discoveries governing tissue specialization, enabling the company to selectively eliminate harmful proteins using small molecules. Its foundational discoveries in Wnt pathway modulation unlocked the broad therapeutic potential of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selection of tissue-specific and disease-selective mRNA splice sites, making them attractive, druggable targets within the cellular command and control centers.

    Biosplice Therapeutics – Revenue Model

    Biosplice Therapeutics makes money by developing and launching regenerative medicines for articular cartilage damage, degenerative disc disease, lung tissue regeneration, osteoarthritis, oncology, neurology, and other degenerative conditions.


    Benchling: A Biotechnology Research and Development Platform
    A cloud-based bioinformatics platform, Benchling delivers innovative solutions for biotechnology research and development.


    Biosplice Therapeutics – Products and Services

    Biosplice Therapeutics clinical developments include:

    • Cirtuvivint for numerous cancers
    • Lorecivivint for osteoarthritis (in Phase 3)
    • A broad pipeline ranging from Alzheimer’s disease to other degenerative conditions

    Biosplice Therapeutics – Challenges Faced

    In February 2022, Biosplice Therapeutics laid off nearly a quarter of its employees and culled a male pattern baldness drug from its pipeline.

    A few months later, in November 2022, the company announced that its bid to transform the treatment of arthritis into cancer ran into a snag with its experimental osteoarthritis drug failing to benefit patients in a pair of Phase 3 clinical trials.

    Biosplice Therapeutics – Funding and Investors

    Biosplice Therapeutics has undertaken 5 funding rounds and raised a total of $778 million. Its latest funding round – Venture Series Unknown Round, was completed on April 15, 2021, and raised a total of $120 million. Recent investors who backed Biosplice Therapeutics include Eventide Asset Management, SymBiosis II, aMoon, Verition Fund Management, Sands Capital, and many others.

    Date Round Number of Investors Money Raised Lead Investor
    April 15, 2021 Venture Series 5 $120 million aMoon Fund, Eventide
    April 01, 2019 Series C 1
    August 06, 2018 Series B 3 $438 million Starling Group, Vickers Venture Partners
    September 01, 2013 Series A 3 $220 million
    September 01, 2012 Seed Round 1

    Biosplice Therapeutics – Growth

    Biosplice Therapeutics witnessed a whopping increase in its valuation from $6 billion in 2016 to $12.8 billion in 2018.

    Biosplice Therapeutics – Partners

    Biosplice Therapeutics has partnered with:

    • Epic Sciences
    • Haisco Pharmaceutical Group Co., Ltd.

    Biosplice Therapeutics – Competitors

    Some main competitors of Biosplice Therapeutics are as follows:

    • Chordia Therapeutics
    • Twist Bioscience
    • Hopewell Therapeutics
    • Lycia Therapeutics
    • Edogena Therapeutics
    • Bionaut Labs

    FAQs

    What does Biosplice Therapeutics do?

    Biosplice Therapeutics is a clinical-stage biotechnology company that develops first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing for major diseases.

    Who is the founder of Biosplice Therapeutics?

    Biosplice Therapeutics was founded by Osman Kibar in 2008.

    Who are the main competitors of Biosplice Therapeutics?

    The main competitors of Biosplice Therapeutics are Chordia Therapeutics, Twist Bioscience, Hopewell Therapeutics, Lycia Therapeutics, Edogena Therapeutics, and Bionaut Labs.

  • Athelas: Bringing Life-Changing Healthcare Products Worldwide

    Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Athelas.

    When patients visit a healthcare facility, their primary aim is to get diagnosed, become well, and go home as soon as possible. Even increasing disease burden and rising healthcare costs in the United States have already led to the emergence of healthcare at-home services.

    The Covid-19 pandemic has also shown people that home healthcare has to be a thing and is much better in several ways than the traditional care model. Athelas is one of the most prominent startups that has made it possible for the world to access healthcare facilities at home.

    This article will tell you everything about Athelas- its founders, startup story, funding, products, business and revenue model, growth, and more.

    Athelas – Company Highlights

    Company Name Athelas
    Headquarters Mountain View, California, United States
    Sector Biotechnology
    Founders Tanay Tandon and Deepika Bodapati
    Founded In 2016
    Valuation $1.5 billion(2022)
    Website Athelas.com

    Athelas – About
    Athelas – Industry
    Athelas – Founders and Team
    Athelas – Startup Story
    Athelas – Mission and Vision
    Athelas – Logo and Tagline
    Athelas – Business Model
    Athelas – Revenue Model
    Athelas – Products and Services
    Athelas – Challenges Faced
    Athelas – Funding and Investors
    Athelas – Growth
    Athelas – Partners
    Athelas – Competitors

    Athelas – About

    Athelas is a developer of remote patient monitoring technology. The team of technologists build the medical products’ next generation at the intersection of hardware and software. Athelas brings world-class tools of hospitals to patients’ homes. It develops blood testing devices that use deep learning and computer vision.

    Moreover, thousands of healthcare organizations utilize Athelas software for medical billing, launching telehealth programs, and providing better patient care. More than 50,000 patients in the US trust the company.

    Athelas – Industry

    Athelas is running a business in the Biotechnology industry. Biotechnology is a branch of science that involves researching and developing products by using biological systems, living creatures, or elements out of them. Biochemistry, genetics, and molecular biology are some fields in biotechnology.

    The global market size of the biotechnology market was valued at $859.94 billion in 2022 and is projected to grow to $1,683.52 billion by 2030, with a CAGR of 8.7% during 2023-2030. The Covid-19 pandemic has positively influenced the growth of the biotechnology market by increasing opportunities and advancements for drug development and manufacturing vaccines for the disease.

    Biotechnology Market Size
    Biotechnology Market Size

    In addition to Athelas, some key players in the global biotechnology industry are AstraZeneca, Sanofi, Gilead Sciences, Inc., Amgen Inc., Abbot Laboratories, and more.

    Athelas – Founders and Team

    Tanay Tandon and Deepika Bodapati are the founders of Athelas.

    Tanay Tandon

    Tanay Tandon attended Stanford University to graduate in Computer Science. He has worked as a Developer at Clipped.me and Software Engineer at Wit.ai.

    Moreover, he is MetaMind’s ex-Researcher and worked as Researcher in Stanford University’s AI Department. Currently, Tanay is the Co-Founder and CEO at Athelas.

    Tanay Tandon - Co-founder and CEO, Athelas
    Tanay Tandon – Co-founder and CEO, Athelas

    Deepika Bodapati

    Deepika Bodapati earned a degree in molecular biology from the University of Cincinnati. She has been an ex-Researcher at NASA Ames Research Center and Stanford University, Multimodality Molecular Imaging LAB (MMIL). Now, she is the Co-Founder of Athelas.

    Deepika Bodapati - Co-founder, Athelas
    Deepika Bodapati – Co-founder, Athelas

    Athelas currently employs more than 210 employees.

    Athelas – Startup Story

    Athelas was founded by Tanay Tandon and Deepika Bodapati in 2016. When they attended Y Combinator the same year, they came across a handful of potential competitors, but none had conducted a clinical trial yet. Tanay and Deepika knew this was the opportunity to stand out to potential partners, customers, and collaborators.

    They knew there would be no company without a trial. Therefore, in 2016, they conducted their first clinical trial for Athelas One at the hospital in Juarez, Mexico, and the hospital instantly saw the value in the device. While testing the device on patients, Tanay and Deepika found that one patient has leukemia after seeing the test results. And hospital took another three weeks to confirm the patient’s leukemia diagnosis.

    During that period, Tanay and Deepika thought that what if all these tests could be done within a few minutes using cheap medical products? That’s when it clicked, and Athelas is continuing its operation with the same idea.


    Top Biotech Startups In India | Best Biotechnology Companies
    Biotechnology is the future of medical science. Here are the best Biotechnology Companies in India. Know about Top 6 Biotech Startups In India.


    Athelas – Mission and Vision

    Athelas aims to bring simple, life-changing healthcare products to people around the world. The company envisions bringing world-class healthcare tools to individuals’ homes.

    Athelas – Logo and Tagline

    Athelas has an attractive tagline reflecting its mission and vision, i.e., “The Future of Healthcare is at the Home.”

    Athelas – Business Model

    Athelas make billing and reimbursement easier for healthcare organizations. The company’s Revenue Cycle Management (RCM) delivers high-quality service, maximizes reimbursements, and equips hospitals with actionable insights into their financial health.

    Moreover, Athelas provides affordable medical testing devices to healthcare providers enabling them to monitor patients’ vitals, such as weight, blood pressure, and blood glucose, without letting patients enter a clinic. It helps improve patient health and engagement while reducing hospitalizations.

    Test Drive Insights | Athelas Revenue Cycle Management

    Athelas – Revenue Model

    Instead of selling its medical devices directly to consumers, Athelas distributes them via healthcare providers. The company charges a subscription for each medical device when sent to the patient’s home.

    Athelas – Products and Services

    The company’s products include Athelas Home, Doctor App, Scribe, Pill Track, Care Management, Revenue Cycle Management, and EHR integration. In addition, it offers a Blood Pressure Monitor, Glucometer, and Weight Scale.

    Athelas – Challenges Faced

    Athelas’s first set of progress was slow. The college workload at Stanford and the increasing costs of hardware iterations made it difficult for the co-founders to operate with the iteration speeds that a normal product needs.

    Athelas – Funding and Investors

    Athelas raised a total of $150.1 million over 4 funding rounds. Its latest funding round – Venture Series Unknown Round, was conducted on January 31, 2021, and secured $59.4 million. 19 investors back the company; the main ones are Sequoia Capital, Fifty Years General Catalyst, and Tribe Capital.

    Date Round Number of Investors Money Raised Lead Investor
    January 31, 2021 Venture Round 7 $59.4 million Tribe Capital
    August 10, 2020 Series B 2 $72 million General Catalyst
    February 1, 2019 Series A 2 $15 million Georges Harik
    August 28, 2017 Seed Round 14 $3.7 million Sequoia Capital

    Athelas – Growth

    Athelas’ monthly active users increased from 2,000 in 2021 to 20,000 in 2022. The company’s estimated annual revenue was $47.7 million per year ($235,953 revenue per employee), with its valuation in January 2022 as $1.5 billion. Furthermore, Athelas’s employee count increased by 38% last year, and the monthly web visits growth rate is -33.49%, with 66,260 monthly visits.

    Athelas – Partners

    Athelas has partnered with many hospitals, clinic groups, physicians, home healthcare agencies, and accountable care organizations. Some of its partners are as follows:

    • Horizon Family Medical Group
    • Providers For Healthy Living
    • Elohim’s Glory House Calls

    Athelas – Competitors

    Below listed are the main competitors of Athelas:

    • HBox
    • Taaso
    • Entia
    • MD Revolution
    • MicroX Labs
    • Longevica
    • YourBio Health
    • ArcDia

    FAQs

    What does Athelas do?

    Athelas is a developer of remote patient monitoring technology. The team of technologists build the medical products’ next generation at the intersection of hardware and software. Athelas brings world-class tools of hospitals to patients’ homes. It develops blood testing devices that use deep learning and computer vision.

    Who are the founders of Athelas?

    Tanay Tandon and Deepika Bodapati are the founders of Athelas.

    Who are the main competitors of Athelas?

    Below listed are the main competitors of Athelas:

    • HBox
    • Taaso
    • Entia
    • MD Revolution
    • MicroX Labs
    • Longevica
    • YourBio Health
    • ArcDia